Comparing the current results to its competitors, Beone Medicines Ltd reported Revenue increase in the 2 quarter 2026 by 29.69 % year on year. The sales growth was above Beone Medicines Ltd 's competitors' average revenue growth of 7.09 %, achieved in the same quarter.
Beone Medicines Ltd 's Comment on Competition and Industry Peers
The company operates in a highly competitive global environment, with its marketed products facing competition in regulated markets worldwide. Competitors include leading global research-based biopharmaceutical companies as well as regional and local firms that develop, produce, and market therapeutic products targeting diseases similar to those in the company's portfolio or pipeline. Key competitors for the company's principal products include AbbVie and Janssen (IMBRUVICA), AstraZeneca (CALQUENCE, IMFINZI), Eli Lilly (JAYPIRCA), Innocare (YINUOKAI), Merck (KEYTRUDA), Bristol Myers Squibb (OPDIVO), Roche (TECENTRIQ), and Merck KGaA (BAVENCIO). The competitive landscape covers territories such as the United States, Europe, Asia Pacific, China, Japan, and Singapore.
October 14, 2025
Sonrotoclax Gains Breakthrough Therapy Designation; TEVIMBRA Approved in Europe for NSCLC Treatment BeOne Medicines Achieves Key Regulatory Milestones in Oncological Advancements In a significant stride for oncological therapeutics, BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology leader, has announced dual achievements in regulatory advancements from both the U.S. Food and Drug Administration (FDA) and the European Commission. These developments signal a progressive phase in their commitment to addressing challenging cancer profiles with innovative treatments. FDA Grants Breakthrough Therapy Designation to SonrotoclaxBeOne Medicines has achieved a pivotal milestone with the F...
August 30, 2025
: The field of oncology continues to evolve at an unprecedented pace with transformative therapeutic strategies emerging to address various malignancies. Recently, BeOne Medicines Ltd., a globally recognized oncology company, has made significant strides in developing novel treatments for challenging hematological and solid tumors. This article highlights the promising advancements of BeOne Medicines, focusing on the potential of Sonrotoclax in Mantle Cell Lymphoma (MCL), the approval of TEVIMBRA for non-small cell lung cancer (NSCLC), and the PRIME designation for BGB-16673 in Waldenström s Macroglobulinemia (WM). Cancer therapies have traditionally followed conventional paths, such as chemotherapy and ...
August 29, 2025
BeOne Medicines Secures European Approval for TEVIMBRA in NSCLC Treatment and Continues Breakthroughs in Oncology Pipeline The biopharmaceutical landscape in oncology has seen significant advancements with BeOne Medicines Ltd., a global leader in the cancer treatment sector, achieving a milestone that further solidifies its position as a pivotal player in the industry. The European Commission has granted approval for the use of TEVIMBRA (Tislelizumab) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by a TEVIMBRA monotherapy as an adjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC) at high risk of relapse. This approval marks a substantive prog...
May 24, 2025
In the rapidly evolving landscape of oncology, innovations are continually reshaping our understanding and treatment of various cancer types. Among the frontrunners in this crucial field, BeiGene, Ltd. (recently rebranded as BeOne Medicines Ltd.) has emerged as a beacon of hope, with a commitment to redefining cancer care globally. As a significant player in the industry, BeiGene s recent announcement regarding its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting promises to shed light on pivotal advancements in hematology and solid tumors. Pioneering Research to be Showcased at ASCO 2025 Scheduled to take place from May 30 to June 3, 2025, in Chicago, the ASCO Annual Meeting ...
April 4, 2025
BeiGene Halts Ociperlimab Clinical Development Following Data Monitoring Committee Review San Carlos, California BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company soon to be rebranded as BeOne Medicines Ltd. has announced the cessation of its clinical development program for Ociperlimab (BGB-A1217). Ociperlimab, an anti-TIGIT antibody, was under investigation as a potential treatment option for lung cancer. The decision to halt the program follows a recommendation from an independent data monitoring committee, which advised the premature termination of the ongoing Phase 3 AdvanTIG trial. The specific details and insights into the committee s decision have not been disclosed...
March 6, 2025
SAN MATEO, California In a significant advancement for cancer treatment, the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA (tislelizumab-jsgr) as a first-line therapy in combination with platinum-based chemotherapy for adults suffering from advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC). This announcement was made today by BeiGene, Ltd. a global oncology company that is set to rebrand itself as BeOne Medicines Ltd. The approval marks a pivotal milestone for patients battling this aggressive form of cancer, which often presents significant treatment challenges due to its aggressive nature and late-stage diagnosis.TEVIMBRA is a monoclonal antibody...
March 1, 2025
In a striking announcement from its San Mateo headquarters, BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) has disclosed its financial results for both the fourth quarter and the entirety of 2024, showcasing a powerful trajectory of growth that reaffirms its stature as a global oncology powerhouse. As the company prepares to transition to the name BeOne Medicines Ltd. it reflects a renewed focus and ambition in the ever-evolving field of cancer treatment.The fourth quarter results underscore BeiGene s relentless commitment to innovation and market leadership. Notably, the continued success of BRUKINSA a key breakthrough treatment for certain types of blood cancers has driven remarkable revenues that f...
Apellis Pharmaceuticals Inc operates under a business model that focuses on the research, development, and commercialization of novel therapies for various medical conditions, with a particular emphasis on complement immunotherapy. They aim to bring innovative drugs to market that can positively impact patients' lives worldwide.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Oculis Holding Ag is a pharmaceutical company that specializes in developing and commercializing innovative ophthalmic treatments. Their business model revolves around conducting in-depth research and development to formulate eye medications that target various ocular diseases. They then seek regulatory approvals and form strategic partnerships to manufacture and distribute their products globally, aiming to improve eye health and provide effective treatment options for patients.
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Sources:
Beone Medicines Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Beone Medicines Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
